Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients with COPD according to GOLD 2011 who have signed informed consent.~2. Patients with airflow limitation of 30-80% post-bronchodilator FEV1 at run-in.~3. Current or ex-smokers with a smoking history of at least 10 pack years~4. Patients with a mMRC score of at least 2 at run-in.~Exclusion Criteria:~1. Patients contraindicated for muscarinic antagonist agents and beta-2 agonists~2. Patients with a history of malignancy of any organ system, treated or untreated, within the last five years~3. Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention~4. Patients who had a COPD exacerbation within 6 weeks prior to screening.~5. Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.~6. Patients with a history of asthma.~7. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to 40 years of age.~8. Patients with a blood eosinophil count of greater than 600 mm/3 during run-in~9. Patients with concomitant pulmonary disease~10. Patients with a history of certain cardiovascular co-morbid conditions~11. Patients with a diagnosis of alpha-1 anti-trypsin deficiency~12. Patients with active pulmonary tuberculosis~13. Patients in the active phase of a pulmonary rehabilitation programme~14. Other protocol-defined inclusion / exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 dose 1 (Type: EXPERIMENTAL): NVA237 dose 1
- Long-acting beta 2-agonist (LABA) (Type: ACTIVE_COMPARATOR): QAB149

Based on this trial design, predict the completion outcome and termination type (if applicable).